Prodrugs:: design and clinical applications

被引:1204
作者
Rautio, Jarkko [1 ]
Kumpulainen, Hanna [1 ]
Heimbach, Tycho [2 ]
Oliyai, Reza [3 ]
Oh, Dooman [4 ]
Jarvinen, Tomi [1 ]
Savolainen, Jouko [5 ]
机构
[1] Univ Kuopio, Dept Pharmaceut Chem, FI-70211 Kuopio, Finland
[2] Novartis Pharmaceut, E Hanover, NJ 07936 USA
[3] Gilead Sci Inc, Foster City, CA 94404 USA
[4] Amgen Inc, Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[5] Fennopharma Ltd, FI-70210 Kuopio, Finland
关键词
D O I
10.1038/nrd2468
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/ or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents. About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend. To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.
引用
收藏
页码:255 / 270
页数:16
相关论文
共 190 条